Ontario Genomics is playing a role
With the power of genomics, we now have a deeper understanding of the genetic basis of life, which is driving innovation across multiple sectors. This allows us to use biotechnology tools in medicine, agriculture and environmental science to solve global challenges and enhance our quality of life.
To boost commercialization, Genome Canada has made its first strategic investment to address Canada’s urgent health and industry challenges. Ontario Genomics is leading a key project that reduces the need for prostate biopsies by predicting the risks of high grade prostate cancer (HGPrCa) with biomarkers from semen.
Read more about Prostate Cancer Predict led by FlowLabs and Dr. Keith Jarvi, Sinai Health.
